Pfizer-BioNTech's Covid-19 booster shot was 95.6% effective in a large study that took place while the Delta variant was prevalent, the companies say
Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” said Albert Bourla, Pfizer Chief Executive Officer.
The data could help the U.S. Food and Drug Administration as it weighs whether to broaden Pfizer’s booster use beyond the seniors and high-risk people permitted under current authorization. The companies reported the findings in a press release and provided few medical details. The results haven’t been published in a peer-reviewed medical journal.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer vaccine is 93% effective in preventing Covid-19 hospitalization among adolescents, CDC study findsThe Pfizer/BioNTech vaccine is 93% effective in preventing hospitalization due to Covid-19 among children ages 12 to 18, according to a study by the US Centers for Disease Control and Prevention. Vaccine effectiveness differed only slightly within that age group, with 91% effectiveness for children age 12 to 15 and 94% effectiveness for those age 16 to 18.
Read more »
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
Read more »
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »
Pfizer booster has 95.6% efficacy against COVID, large study showsA booster shot of the Pfizer-BioNTech vaccine is 95.6% effective against the coronavirus, compared with those who only had the first two initial doses, according to a large study released Thursday.Why it matters: The study, which had more than 10,000 participants aged 16 and older, is the first controlled, randomized trial looking at boosters and their effectiveness, the companies said.Get market news worthy of your time with Axios Markets. Subscribe for free.The companies said the study was con
Read more »
Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies sayA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy -- 95.6% -- against Covid-19 in a Phase 3 trial, the companies announced on Thursday. They noted that 'efficacy was consistent irrespective of age, sex, race, ethnicity or comorbid conditions.'
Read more »
Pfizer Vaccine 93% Effective At Preventing Hospitalization In Kids Ages 12-18More good news about the effectiveness of Pfizer’s COVID-19 vaccine in adolescents ages 12-18 — this time, about hospitalization rates The Centers for Disease Control and Prevention just rolled out new stats pointing to Pfizer’s COVID-19 vaccine being safe and effective at preventing hospitalization in kids ages 12-18. The CDC’s latest study shows that Pfizer’s […]
Read more »